​

KalVista Pharmaceuticals (KALV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

KALV Stock Forecast

KalVista Pharmaceuticals (KALV) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $22.67, with a high of $28.00 and a low of $20.00. This represents a 66.45% increase from the last price of $13.62.

$5 $10 $15 $20 $25 $30 High: $28 Avg: $22.67 Low: $20 Last Closed Price: $13.62

KALV Stock Rating

KalVista Pharmaceuticals stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 12 Strong Sell Sell Hold Buy Strong Buy

KALV Price Target Upside V Benchmarks

TypeNameUpside
StockKalVista Pharmaceuticals66.45%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$28.00
Last Closing Price$13.62$13.62$13.62
Upside/Downside--105.58%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2537---10
Aug, 2537---10
Jul, 2537---10
Jun, 2537---10
May, 2537---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Serge BelangerNeedham$28.00$11.25148.89%105.58%
Sep 06, 2024Andrew FeinH.C. Wainwright$20.00$12.8755.40%46.84%
Sep 06, 2024Joseph SchwartzLeerink Partners$20.00$12.8755.40%46.84%
Jul 08, 2022Needham$38.00$10.98246.08%179.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 12, 2025CitigroupOutperformOutperformhold
Sep 06, 2024H.C. WainwrightBuyBuyhold
Sep 06, 2024Leerink PartnersOutperformOutperformhold
Feb 03, 2023SVB LeerinkOutperformOutperformhold
Jul 08, 2022SVB LeerinkOutperformOutperformhold
Jul 08, 2022NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 $5 Apr 24 Apr 25 Apr 26 Apr 27 Apr 28 Apr 29
Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29
Reported$-3.44-----
Avg Forecast$-3.03$-3.63$-2.76$-1.06$0.68$2.39
High Forecast$-2.85$-3.46$-1.74$-0.02$1.14$4.03
Low Forecast$-3.23$-3.83$-3.56$-2.20$0.38$1.33
Surprise %13.53%-----

Revenue Forecast

$0 $120M $240M $360M $480M $600M Apr 24 Apr 25 Apr 26 Apr 27 Apr 28 Apr 29
Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29
Reported------
Avg Forecast$4.46M$5.92M$42.74M$149.88M$271.40M$384.00M
High Forecast$6.81M$9.04M$58.41M$149.88M$414.34M$586.24M
Low Forecast$2.94M$3.91M$35.87M$149.88M$179.15M$253.47M
Surprise %------

Net Income Forecast

$-200M $-130M $-60M $10M $80M $150M Apr 24 Apr 25 Apr 26 Apr 27 Apr 28 Apr 29
Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29
Reported$-126.64M$-183.44M----
Avg Forecast$-111.87M$-134.12M$-97.52M$-58.31M$24.92M$87.92M
High Forecast$-104.85M$-127.38M$-63.97M$-735.73K$41.99M$148.12M
Low Forecast$-118.88M$-140.86M$-131.08M$-80.93M$13.91M$49.07M
Surprise %13.21%36.77%----

KALV Forecast FAQ

Is KalVista Pharmaceuticals stock a buy?

KalVista Pharmaceuticals stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that KalVista Pharmaceuticals is a favorable investment for most analysts.

What is KalVista Pharmaceuticals's price target?

KalVista Pharmaceuticals's price target, set by 12 Wall Street analysts, averages $22.67 over the next 12 months. The price target range spans from $20 at the low end to $28 at the high end, suggesting a potential 66.45% change from the previous closing price of $13.62.

How does KalVista Pharmaceuticals stock forecast compare to its benchmarks?

KalVista Pharmaceuticals's stock forecast shows a 66.45% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and outperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for KalVista Pharmaceuticals over the past three months?

  • September 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is KalVista Pharmaceuticals’s EPS forecast?

KalVista Pharmaceuticals's average annual EPS forecast for its fiscal year ending in April 2026 is $-2.76, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $-1.06 in 2027, $0.68 in 2028, and $2.39 in 2029.

What is KalVista Pharmaceuticals’s revenue forecast?

KalVista Pharmaceuticals's average annual revenue forecast for its fiscal year ending in April 2026 is $42.74M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $149.88M, followed by $271.4M for 2028, and $384M for 2029.

What is KalVista Pharmaceuticals’s net income forecast?

KalVista Pharmaceuticals's net income forecast for the fiscal year ending in April 2026 stands at $-97.522M, representing a -46.84% decrease from the reported $-183M in 2025. Projections indicate $-58.309M in 2027, $24.92M in 2028, and $87.92M in 2029.